1.0君实生物/en/js3333线路检测中心(中国)有限公司-Baidu百科rich600338Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency
/wp-content/uploads/2022/12/特瑞普利单抗-1-1024x683.png1024683SHANGHAI, China, November 24, 2022 (GLOBE NEWSWIRE) – Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company has submitted a marketing authorization application (“MAA”) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (“MHRA”) for toripalimab. The indications requested in the MAA are: 1) Toripalimab, in combination with cisplatin and gemcitabine, for the first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma (“NPC”) and 2)Toripalimab, in combination with paclitaxel and cisplatin, for the first-line treatment of patients with unresectable locally advanced/recurrent